Login / Signup

Impact of 13-valent pneumococcal conjugate vaccine on laboratory-confirmed pneumococcal meningitis and purulent meningitis among children ˂5 years in Cameroon, 2011-2018.

John Njuma LibweaMark A FletcherPaul Koki NdomboAngeline BoulaNadesh Ashukem TakuMadeleine Ngo BalebaRachel Sandrine Kingue BebeyEric Gaston Nkolo MvienaJean TageubeMarie Kobela MbolloSinata Koulla-ShiroShabir MadhiBerthe-Marie Njanpop-LafourcadeMohammad AliElizabeth BegierJoanna SouthernRohini BeavonBradford Gessner
Published in: PloS one (2021)
Four to seven years after PCV13 introduction, the proportion of pneumococcal meningitis due to vaccine serotypes has declined, mainly due to reductions of serotypes 6A/6B, 1, 19A, and 23F; nevertheless, PCV13 VSTs remain common. Because the analyzed surveillance system was not consistent or population based, we could not estimate incidence or overall impact; this emphasizes the need for improved surveillance to document further the utility of PCV13 immunization in Cameroon.
Keyphrases
  • cerebrospinal fluid
  • public health
  • young adults
  • risk factors